<DOC>
	<DOCNO>NCT03093415</DOCNO>
	<brief_summary>hepatitis C virus ( HCV ) traditionally treat subspecialty health center give complexity older pegylated interferon containing regimen , formerly standard care . This model persist modern era direct anti-viral agent ( DAAs ) despite relative simplicity , create bottleneck human resource necessary fight large infectious epidemic North America . In addition , stigma fear cost lead payer restrict treatment People Who Inject Drugs ( PWIDs ) , even though majority new infection occur population . This study evaluate effectiveness treatment HCV elbasvir-grasoprevir PWIDs real world , community health clinic setting . There two prospective cohort PWIDs 25 patient , primary care-based community health clinic Portland , Oregon . Cohort one actively engage ambulatory medication assist therapy buprenorphine extend release injectable naltrexone . Cohort two maintains active injection drug use needle exchange risk reduction education . These group compare 50 patient retrospective cohort people substance use disorder tertiary care hepatology-based treatment program . All patient genotype 1 4 HCV treat elbasvir-grasoprevir 12 week . The investigator hypothesize difference sustain viremic response 12 48 week post-completion treatment ( SVR 12 , 48 ) treat patient community health clinic set compare standard-of-care subspecialty setting .</brief_summary>
	<brief_title>Hepatitis C Treatment PWIDs : MAT Syringe Exchange Assisted-therapy v Standard Care</brief_title>
	<detailed_description>Hepatitis C traditionally treat subspecialty health center give complexity older pegylated interferon containing regimen , formerly standard care . This model persist modern era direct anti-viral agent ( DAAs ) despite relative simplicity , create bottleneck human resource necessary fight large infectious epidemic North America . In addition , stigma fear cost lead payer restrict treatment People Who Inject Drugs ( PWIDs ) , even though majority new infection occur population . This study evaluate effectiveness treatment hepatitis C virus ( HCV ) elbasvir-grasoprevir people inject drug ( PWIDs ) real world , community health clinic setting . There two prospective cohort PWIDs 25 patient , primary care-based community health clinic Portland , Oregon . Cohort one actively engage ambulatory medication assist therapy buprenorphine extend release injectable naltrexone . Cohort two maintains active injection drug use needle exchange risk reduction education . These group compare 50 patient retrospective cohort people substance use disorder tertiary care hepatology-based Academic Health Center . All patient genotype 1 4 HCV treat elbasvir-grasoprevir 12 week . The investigator exclude patient : age 18 ; history liver transplant ; fail past treatment HCV ; AST Platelet Ratio Index ( APRI ) &gt; 0.7 APRI &gt; 0.7 fibrosure/fibroscan F2 le ; patient genotype 1a NS5a resistance RAVs ; clinical radiologic evidence cirrhosis ; aminotransferase level &gt; 10x upper limit normal ; co-infected hepatitis B HIV . The investigator hypothesize difference sustain viremic response 12 48 week post-completion treatment ( SVR 12 , 48 ) treat patient DAA community health clinic set compare standard-of-care subspecialty setting .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Substance Abuse , Intravenous</mesh_term>
	<criteria>Genotype 1b genotype 1a without baseline NS5A resistance Genotype 4 APRI Score &lt; 0.7 ; &gt; 0.7 Fibrosure/Fibrotest Fibroscan score F2 le No clinical laboratory evidence cirrhosis Readiness treatment base ability make &gt; 2/3 sequential office visit Patients must assess decisionmaking capacity , capable consenting , display evidence overt intoxication . Clinical Laboratory Evidence Cirrhosis Elevated prothrombin time unrelated anticoagulation , hemoglobin level less 12.3 g/L female &lt; 14 g/L male , platelet count &lt; 150 Ã— 109 cells/L ) , WBC &lt; 4.0 x103/mm3 , aminotransferase level 10 time upper limit normal , albumin level &lt; 3.5 g/L . Previous treatment hepatitis C infection Hepatocellular carcinoma HIV hepatitis B virus coinfection Subjects take medication contraindicate administer Zepatier include phenytoin , carbamazepine , rifampin , St. John 's Wort , cyclosporine AND unable change medication one without interaction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>People Who Inject Drugs</keyword>
	<keyword>PWID</keyword>
	<keyword>Medication Assisted Therapy</keyword>
	<keyword>MAT</keyword>
	<keyword>Needle Exchange Program</keyword>
</DOC>